LTRN - Lantern Pharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-18.51M

Cash

47.95M

Avg Qtr Burn

-3.514M

Short % of Float

2.08%

Insider Ownership

17.47%

Institutional Own.

24.52%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LP-100 (Irofulven) Details Cancer, Castration-resistant prostate cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LP-300 Details Non-small cell lung carcinoma, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LP-284 Details Cancer, Non-Hodgkin lymphoma, High-grade Glioma , Mantle cell lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LP-184 Details Cancer, Solid tumor/s, Central nervous system illness	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.